Coronary Stents: Breaking J&J's Lock on the Market
This article was originally published in Start Up
Executive Summary
Despite increasing worldwide competition, the coronary stent market continues to be technology driven, as new devices allow interventional cardiologists to customize treatment for different kinds of lesions. In the US, J&J’s patent will be key to the evolution of the market, but overseas, competitors are making inroads, often with stents that address issues not satisfactorily addressed by J&J’s stent.
You may also be interested in...
World Congress of Cardiology: DES Safety Dominates Discussions
While the greater efficacy of drug-eluting stents (DES) compared to bare-metal stents is widely accepted, over the past year, data has continued to build showing that first-generation DES also have a higher late-stage in-stent thrombosis risk, a complication that can cause death 30% of the time, according to some estimates. The findings of these studies had some physicians at this year's World Congress of Cardiology calling for "an immediate halt to DES overuse." However, most conceded that additional randomized trials will be needed to fully understand the potential risks associated with these devices.
Shades of BENESTENT in the Aneurysm World
UK investigators' recent decision to call an early halt to enrollment in a major study comparing neurosurgical clipping to endovascular coil treatment of ruptured cerebral aneurysms may signal a significant change of practice habits in a critical area of neurology. The findings, if they're as good as they appear to be, could do to surgical clipping and endovascular coils what the BENESTENT trials of the early 1990s did to promote stenting over balloon angioplasty in patients with coronary artery disease.
Shades of BENESTENT in the Aneurysm World
UK investigators' recent decision to call an early halt to enrollment in a major study comparing neurosurgical clipping to endovascular coil treatment of ruptured cerebral aneurysms may signal a significant change of practice habits in a critical area of neurology. The findings, if they're as good as they appear to be, could do to surgical clipping and endovascular coils what the BENESTENT trials of the early 1990s did to promote stenting over balloon angioplasty in patients with coronary artery disease.